Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NBI-5788 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| NBI-5788 | DRUG | - |
Inclusion Criteria: * Male or female, 18 to 55 years of age * Diagnosed with relapsing multiple sclerosis, with at least one relapse in the last two years * Females must not plan on becoming pregnant * Females must either be post-menopausal, surgically incapable of bearing children, or practicing a...
NBI-5788 is an investigational small molecule being studied for the treatment of Multiple Sclerosis (MS). It is an altered peptide ligand evaluated in patients with relapsing MS. The drug is in Phase 2 clinical development and is not approved by regulatory authorities.
NBI-5788 is being developed by Neurocrine Biosciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker NBIX. The company is conducting clinical research on this investigational drug for Multiple Sclerosis.
NBI-5788 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of Multiple Sclerosis, and its Phase 2 trial has been completed.
NBI-5788 has one completed Phase 2 clinical trial registered as NCT00079495, titled "Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)." This trial enrolled 150 participants and was a randomized, double-blind study without a control group.
Yes, NBI-5788 is an altered peptide ligand. In clinical trials, it is described as such, and it is being investigated for its potential therapeutic effect in patients with relapsing Multiple Sclerosis. This classification reflects its mechanism as a modified peptide designed to modulate immune responses.